FDA GLP-1 eye warning: on November 9, 2026, the U.S. Food and Drug Administration said it is requiring a new safety warning on the labeling of all GLP-1 receptor agonist medicines. The warning covers a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). This article explains what FDA said, what evidence it reviewed and what the action does not do, using FDA’s own pages, checked on November 17, 2026.
Quick answer: FDA has not withdrawn any GLP-1 medicine or changed any approval. It is requiring a label warning about a rare eye condition, NAION, for the whole class, including semaglutide, tirzepatide, liraglutide and dulaglutide products. FDA calls the risk “potential” and the events “rare.” The communication is about FDA-approved prescription medicines. It does not mention compounded products or research material.
This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.
What did FDA announce?
FDA published a Drug Safety Communication on November 9, 2026, and a matching MedWatch alert the same day (FDA, 2026; MedWatch alert). The communication says: “FDA is requiring that application holders add information about the risk for NAION” to the Warnings and Precautions section of the labeling. The requirement applies to “application holders for all GLP-1 RA medications.” Application holders are the companies that hold the FDA approvals.
FDA describes NAION as “a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss.” FDA also says the underlying cause of NAION is not completely understood.
Which medicines does the labeling change cover?
The communication lists the GLP-1 receptor agonist medicines it covers. Table 1 shows that list as we read it on November 17, 2026.
Medicines listed in FDA’s November 9, 2026 communication
| Active ingredient | Brand names listed by FDA |
|---|---|
| Semaglutide | Ozempic, Rybelsus, Wegovy |
| Tirzepatide | Mounjaro, Zepbound |
| Liraglutide | Victoza, Saxenda |
| Liraglutide with insulin degludec | Xultophy |
| Dulaglutide | Trulicity |
| Exenatide | Byetta |
| Lixisenatide with insulin glargine | Soliqua |
| Orforglipron | Foundayo |
FDA adds two notes to its list. The Byetta application “was voluntarily withdrawn (not for reasons of safety or effectiveness).” And tirzepatide acts on two receptors: “Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist.”
What evidence did FDA review?
FDA describes several kinds of data (FDA, 2026):
- Clinical trials. FDA pooled 126 trials with 134,253 patients. It found 15 probable NAION events: 10 in patients treated with GLP-1 receptor agonists and 5 in patients who received placebo. That is 6.4 events per 100,000 person-years with GLP-1 receptor agonists, “compared to 3.8 events per 100,000 PY in comparator-treated patients.”
- Insurance-claims study. A study in FDA’s Sentinel system looked at adults with type 2 diabetes who started one of three drug classes. FDA reports “no statistically significant increase in the risk for NAION with GLP1-RAs compared to SGLT-2 inhibitors.” It reports that “an increased risk of NAION was observed with GLP1-RAs compared to DPP-4 inhibitors.”
- Published studies. FDA says the more rigorous published observational studies “consistently reported an increased risk” against the same two comparison classes.
- Adverse event reports. FDA reviewed reports in its adverse event database and says they were hard to interpret. It also says NAION cases have been reported for all currently marketed GLP-1 receptor agonist products.
- Animal data. FDA says its review of animal data did not identify a mechanism for how these medicines could raise the risk.
FDA’s conclusion is measured: “FDA concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs.”
What does the action not do?
The communication is a labeling action. It does not withdraw a medicine, change an approved use or restrict prescribing. The page we read does not say that any label has been updated yet, and it gives no deadline for the companies. It does not name the legal provision FDA is using.
The communication also does not mention compounded drugs, retatrutide or products sold as research material. Its list covers FDA-approved medicines only. Unapproved products have no FDA-approved labeling, so a required labeling change does not reach them.
FDA’s page includes recommendations for patients and for health care professionals. We do not repeat medical guidance here. Anyone taking a prescription GLP-1 medicine should read FDA’s communication and speak with their own health care professional.
What does this mean for research-grade GLP-1 peptides?
Nothing changes in the legal status of research material. The notice is about medicines that people take under a prescription. Research-grade peptides are laboratory reagents. They are not medicines and are not a substitute for an approved prescription medicine. A new warning on approved products is one more reminder that these compounds have real safety questions that FDA tracks through labeling, trials and adverse event reports. None of that oversight applies to a research vial.
Research-grade semaglutide and tirzepatide in our catalog are sold for laboratory research use only, not for human or veterinary use. For background, see semaglutide side effects in trials, tirzepatide side effects in trials and what research use only means.
Frequently asked questions about the FDA GLP-1 eye warning
What is NAION?
Non-arteritic anterior ischemic optic neuropathy. FDA describes it as a rare condition that can cause sudden, painless loss of vision in one eye, which can be permanent.
Did FDA say GLP-1 medicines cause NAION?
FDA said there is a “potential increased risk” of rare NAION events. It did not identify a mechanism in animal data.
Did FDA take any GLP-1 medicine off the market?
No. The action adds a warning to labeling. Approvals are unchanged.
Does the warning apply to tirzepatide?
Yes. FDA’s list includes Mounjaro and Zepbound, and notes that tirzepatide is a GIP and GLP-1 receptor agonist.
Does the communication cover compounded or research-labeled products?
It does not mention them. It addresses the labeling of FDA-approved medicines.
What to know now
- Action: FDA Drug Safety Communication dated November 9, 2026, requiring a class-wide labeling change.
- Risk named: NAION, a rare eye condition; FDA calls the increased risk “potential.”
- Where it goes: the Warnings and Precautions section of each GLP-1 receptor agonist label.
- Evidence: 15 probable events in 126 pooled trials, a Sentinel study, published studies and adverse event reports.
- Not changed: approvals, approved uses and the rules on compounding.
- Research grade: for laboratory research use only, not for human or veterinary use.
What we’re watching
Updated labels for each listed medicine, which will show the final warning text. Any follow-up FDA communication with new data. And whether FDA adds the eye-risk finding to its page on unapproved GLP-1 drugs, covered in our semaglutide legal status guide.